新型口服抗凝药在房颤患者治疗中的研究进展(4)
[18]Granger CB,Alexander JH,McMurray JJ,et al.Apixaban versus warfarin inpatients with atrial fibrillation[J].N Engl J Med,2011,365(11):981-992.
[19]李庆勇,牛锁成,何贵生,等.阿哌沙班治疗非瓣膜性房颤有效性和安全性Meta分析[J].重庆医学,2014,43(4):437.
[20]Connolly SJ,Eikelboom J,Joyner C,et al.Apixaban in patients with atrial fibrillation[J].N Engl J Med,2011,364(9):806-817.
[21]Bounameaux H,Camm AJ.Edoxaban:an update on the new oral direct factor Xa inhibitor[J].Drugs,2014,74(11):1209-1231.
[22]Yin QQ,Tetsuya K,Miller R.Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation[J].Eur J Clin Pharmacol,2014,70(11):1339-1351.
[23]Giugliano RP,Pinar JI,Ruzyllo W,et al.Edoxaban versus warfarin in patients with artrial fibrillation[J].N Engl J Med,2013,369(22):2093.
[24]王鵬,戴海龙,光雪峰.房颤抗凝治疗进展[J].中国心血管病研究,2017,15(3):200-203.
[25]沈珠甫.新型口服抗凝药在老年非瓣膜性房颤患者中的临床应用[J].中国实用医药,2018,13(18):96-97.
(收稿日期:2018-09-10 本文编辑:刘克明), 百拇医药(束长城 侯振世)
[19]李庆勇,牛锁成,何贵生,等.阿哌沙班治疗非瓣膜性房颤有效性和安全性Meta分析[J].重庆医学,2014,43(4):437.
[20]Connolly SJ,Eikelboom J,Joyner C,et al.Apixaban in patients with atrial fibrillation[J].N Engl J Med,2011,364(9):806-817.
[21]Bounameaux H,Camm AJ.Edoxaban:an update on the new oral direct factor Xa inhibitor[J].Drugs,2014,74(11):1209-1231.
[22]Yin QQ,Tetsuya K,Miller R.Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation[J].Eur J Clin Pharmacol,2014,70(11):1339-1351.
[23]Giugliano RP,Pinar JI,Ruzyllo W,et al.Edoxaban versus warfarin in patients with artrial fibrillation[J].N Engl J Med,2013,369(22):2093.
[24]王鵬,戴海龙,光雪峰.房颤抗凝治疗进展[J].中国心血管病研究,2017,15(3):200-203.
[25]沈珠甫.新型口服抗凝药在老年非瓣膜性房颤患者中的临床应用[J].中国实用医药,2018,13(18):96-97.
(收稿日期:2018-09-10 本文编辑:刘克明), 百拇医药(束长城 侯振世)